CoChat

Mutational signatures of ionizing radiation in second malignancies

Open access
Behjati, Sam, Gundem, Gunes, Wedge, David C., Roberts, Nicola D., Tarpey, Patrick S., Cooke, Susanna L., Van Loo, Peter, Alexandrov, Ludmil B., Ramakrishna, Manasa, Davies, Helen, Nik-Zainal, Serena, Hardy, Claire, Latimer, Calli, Raine, Keiran M., Stebbings, Lucy, Menzies, Andy, Jones, David, Shepherd, Rebecca, Butler, Adam P., Teague, Jon W., Jorgensen, Mette, Khatri, Bhavisha, Pillay, Nischalan, Shlien, Adam, Futreal, P. Andrew, Badie, Christophe, ICGC Prostate Group, Cooper, Colin S., Eeles, Rosalind A., Easton, Douglas, Foster, Christopher, Neal, David E., Brewer, Daniel S., Hamdy, Freddie, Lu, Yong-Jie, Lynch, Andrew G., Massi, Charlie E., Ng, Anthony, Whitaker, Hayley C., Yu, Yongwei, Zhang, Hongwei, Bancroft, Elizabeth, Berney, Dan, Camacho, Niedzica, Corbishley, Cathy, Dadaev, Tokhir, Dennis, Nening, Dudderidge, Tim, Edwards, Sandra, Fisher, Cyril, Ghori, Jilur, Gnanapragasam, Vincent J., Greenman, Christopher, Hawkins, Steve, Hazell, Steven, Howat, Will, Karaszi, Katalin, Kay, Jonathan, Kote-Jarai, Zsofia, Kremeyer, Barbara, Kumar, Pardeep, Lambert, Adam, Leongamornlert, Daniel, Livni, Naomi, Luxton, Hayley, Matthews, Lucy, Mayer, Erik, Merson, Susan, Nicol, David, Ogden, Christopher, O’Meara, Sarah, Pelvender, Gill, Shah, Nimish C., Tavare, Simon, Thomas, Sarah, Thompson, Alan, Verrill, Claire, Warren, Anne, Zamora, Jorge, McDermott, Ultan, Bova, G. Steven, Richardson, Andrea L., Flanagan, Adrienne M., Stratton, Michael R., Campbell, Peter J. · 2016 · Nature Communications

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Abstract

Ionizing radiation is a potent carcinogen, inducing cancer through DNA damage. The signatures of mutations arising in human tissues following in vivo exposure to ionizing radiation have not been documented. Here, we searched for signatures of ionizing radiation in 12 radiation-associated second malignancies of different tumour types. Two signatures of somatic mutation characterize ionizing radiation exposure irrespective of tumour type. Compared with 319 radiation-naive tumours, radiation-associated tumours carry a median extra 201 deletions genome-wide, sized 1–100 base pairs often with microhomology at the junction. Unlike deletions of radiation-naive tumours, these show no variation in density across the genome or correlation with sequence context, replication timing or chromatin structure. Furthermore, we observe a significant increase in balanced inversions in radiation-associated tumours. Both small deletions and inversions generate driver mutations. Thus, ionizing radiation generates distinctive mutational signatures that explain its carcinogenic potential.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms12605

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Indels in radiation-associated tumours. (a) Indel/substitution ratio. Shown is the indel/substitution ratio for each tumour. The ratio was significantly increased in radiation-associated second malignancies (0.0003, linear mixed effects model). Each dot represents a tumour. Different colours represent different tumour types (see legend, top right). Boxplots: vertical line – median; whiskers – minimum and maximum without outliers. (b) Deletion/insertion ratio. Shown is the deletion/insertion ratio of every tumour. Deletions were significantly (*) enriched in radiation-associated second malignancies (P<2.2 × 10−16, linear mixed effects model) and in breast tumours with germline BRCA1 or BRCA2 deficiency. Symbols, boxplots as per a. (c) Clonal versus subclonal indels in radiation-associated second malignancies. Shown are the absolute clonal (early) and subclonal (late) indel burdens of each tumour, by indel type. Amongst clonal indels, deletions were significantly enriched. P-values refer to the comparison of proportion of deletions/other indels in clonal versus subclonal indels (Fisher's exact test). (d) Indel likelihood across the genome. Shown is the probability of deletion or insertion to occur (vertical axis) across different regions of the genome (horizontal axis). The probability was modelled on the basis of associations between indels and genomic properties (see Methods). Chromosome 14 is shown as a representative chromosome. Radiation-associated indels were compared to indels of 35 non-radiation-associated osteosarcomas. Radiation-associated deletions, but not insertions, followed a more uniform distribution across the genome than in radiation-naive samples. (e) Distribution of indels in relation to genomic features. Comparison of the mutation density of radiation versus non-radiation indels in relation to genomic features. X axis: ratio of mutation density of non-radiation-associated indels or radiation-associated indels over background density. Y axis: genomic feature. The distribution of insertions in both radiation-associated and radiation-naïve tumours correlated with several genomic features, with few significant differences (asterisk) between the two. In contrast, the distribution of deletions in radiation-induced cancers, but not in radiation-naive tumours, showed little variability and resembled the background distribution more closely. Thus, significant differences (asterisk) were seen in the deletion density in relation to genomic features comparing radiation-associated and radiation-naïve tumours. P-values are detailed in Supplementary Data 4.
Figure 1 Indels in radiation-associated tumours. (a) Indel/substitution ratio. Shown is the indel/substitution ratio for each tumour. The ratio was significantly increased in radiation-associated second malignancies (0.0003, linear mixed effects model). Each dot represents a tumour. Different colours represent different tumour types (see legend, top right). Boxplots: vertical line – median; whiskers – minimum and maximum without outliers. (b) Deletion/insertion ratio. Shown is the deletion/insertion ratio of every tumour. Deletions were significantly (*) enriched in radiation-associated second malignancies (P<2.2 × 10−16, linear mixed effects model) and in breast tumours with germline BRCA1 or BRCA2 deficiency. Symbols, boxplots as per a. (c) Clonal versus subclonal indels in radiation-associated second malignancies. Shown are the absolute clonal (early) and subclonal (late) indel burdens of each tumour, by indel type. Amongst clonal indels, deletions were significantly enriched. P-values refer to the comparison of proportion of deletions/other indels in clonal versus subclonal indels (Fisher's exact test). (d) Indel likelihood across the genome. Shown is the probability of deletion or insertion to occur (vertical axis) across different regions of the genome (horizontal axis). The probability was modelled on the basis of associations between indels and genomic properties (see Methods). Chromosome 14 is shown as a representative chromosome. Radiation-associated indels were compared to indels of 35 non-radiation-associated osteosarcomas. Radiation-associated deletions, but not insertions, followed a more uniform distribution across the genome than in radiation-naive samples. (e) Distribution of indels in relation to genomic features. Comparison of the mutation density of radiation versus non-radiation indels in relation to genomic features. X axis: ratio of mutation density of non-radiation-associated indels or radiation-associated indels over background density. Y axis: genomic feature. The distribution of insertions in both radiation-associated and radiation-naïve tumours correlated with several genomic features, with few significant differences (asterisk) between the two. In contrast, the distribution of deletions in radiation-induced cancers, but not in radiation-naive tumours, showed little variability and resembled the background distribution more closely. Thus, significant differences (asterisk) were seen in the deletion density in relation to genomic features comparing radiation-associated and radiation-naïve tumours. P-values are detailed in Supplementary Data 4.CC BY · PubMed Central
Figure 2 Balanced inversions in radiation-associated tumours. (a) Overview of rearrangements. Tumours exhibited tumour-type specific features. Balanced inversions (black bars) were found in every tumour, except PD7530a. (b) Example of a balanced inversion in PD7188a. A 0.9 Mb inversion. The inversion was validated by PCR across the breakpoint (gel image) and by split reads. Note that the split reads carried a heterozygous SNP at the head end.
Figure 2 Balanced inversions in radiation-associated tumours. (a) Overview of rearrangements. Tumours exhibited tumour-type specific features. Balanced inversions (black bars) were found in every tumour, except PD7530a. (b) Example of a balanced inversion in PD7188a. A 0.9 Mb inversion. The inversion was validated by PCR across the breakpoint (gel image) and by split reads. Note that the split reads carried a heterozygous SNP at the head end.CC BY · PubMed Central
Figure 3 Indels in prostate tumours. (a) Indels in radiation-naive versus radiation-exposed prostate tumours. Shown is the indel burden, by indel subtype, found in radiation-naive and in radiation-exposed prostate tumours. In radiation-exposed tumours radiotherapy had been administered to the primary tumour before formation of metastases. Deletions were significantly enriched in radiation-exposed tumours (P=0.0002, generalized linear model). Note that radiation-associated tumours with confounding BRCA1 or BRCA2 deficiency were excluded from the statistical analysis (cases PD13412 and PD11335). (b) Indels in tumours from a patient whose primary lesion was treated with ionizing radiation after formation of metastases. Shown are indels that were found exclusively in the primary lesion and indels found in all other lesions. Deletions were significantly enriched amongst indels exclusive to the primary lesion. Comparison by Fisher's exact test, of the ratio of deletions over other indels.
Figure 3 Indels in prostate tumours. (a) Indels in radiation-naive versus radiation-exposed prostate tumours. Shown is the indel burden, by indel subtype, found in radiation-naive and in radiation-exposed prostate tumours. In radiation-exposed tumours radiotherapy had been administered to the primary tumour before formation of metastases. Deletions were significantly enriched in radiation-exposed tumours (P=0.0002, generalized linear model). Note that radiation-associated tumours with confounding BRCA1 or BRCA2 deficiency were excluded from the statistical analysis (cases PD13412 and PD11335). (b) Indels in tumours from a patient whose primary lesion was treated with ionizing radiation after formation of metastases. Shown are indels that were found exclusively in the primary lesion and indels found in all other lesions. Deletions were significantly enriched amongst indels exclusive to the primary lesion. Comparison by Fisher's exact test, of the ratio of deletions over other indels.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Cited by

See all 274

Metadata

Authors
Behjati, S., Gundem, G., Wedge, D. C., Roberts, N. D., Tarpey, P. S., Cooke, S. L., Van Loo, P., Alexandrov, L. B., Ramakrishna, M., Davies, H., Nik-Zainal, S., Hardy, C., Latimer, C., Raine, K. M., Stebbings, L., Menzies, A., Jones, D., Shepherd, R., Butler, A. P., Teague, J. W., Jorgensen, M., Khatri, B., Pillay, N., Shlien, A., Futreal, P. A., Badie, C., ICGC Prostate Group, Cooper, C. S., Eeles, R. A., Easton, D., Foster, C., Neal, D. E., Brewer, D. S., Hamdy, F., Lu, Y.-J., Lynch, A. G., Massi, C. E., Ng, A., Whitaker, H. C., Yu, Y., Zhang, H., Bancroft, E., Berney, D., Camacho, N., Corbishley, C., Dadaev, T., Dennis, N., Dudderidge, T., Edwards, S., Fisher, C., Ghori, J., Gnanapragasam, V. J., Greenman, C., Hawkins, S., Hazell, S., Howat, W., Karaszi, K., Kay, J., Kote-Jarai, Z., Kremeyer, B., Kumar, P., Lambert, A., Leongamornlert, D., Livni, N., Luxton, H., Matthews, L., Mayer, E., Merson, S., Nicol, D., Ogden, C., O’Meara, S., Pelvender, G., Shah, N. C., Tavare, S., Thomas, S., Thompson, A., Verrill, C., Warren, A., Zamora, J., McDermott, U., Bova, G. S., Richardson, A. L., Flanagan, A. M., Stratton, M. R., & Campbell, P. J.
Affiliations
  • University of Cambridge (GB)
  • Wellcome Sanger Institute (GB)
  • Centre for Human Genetics (GB)
  • Royal National Orthopaedic Hospital NHS Trust (GB)
  • Hospital for Sick Children (CA)
  • The University of Texas MD Anderson Cancer Center (US)
  • Public Health England (GB)
  • University of East Anglia (GB)
  • Institute of Cancer Research (GB)
  • University of Liverpool (GB)
  • Queen Mary University of London (GB)
  • Chinese University of Hong Kong (HK)
  • Second Military Medical University (CN)
  • St George's Hospital (GB)
  • Royal Marsden NHS Foundation Trust (GB)
  • Cancer Research UK (GB)
  • Brigham and Women's Hospital (US)
Corresponding author
Campbell, Peter J.
Venue
Nature Communications
Published
2016-09-12
Volume
7
Issue
1
Pages
12605-12605
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2520931435
Cited by
274
References
44
Citations by year
2026: 22 · 2025: 30 · 2024: 23 · 2023: 22 · 2022: 22 · 2021: 29 · 2020: 44 · 2019: 31 · 2018: 28 · 2017: 22
FWCI
11.25
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Tampere University Institutional Repository (Tampere University) (publishedVersion, cc-by)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
  • UEA Digital Repository (University of East Anglia) (acceptedVersion, cc-by)
  • Lirias (KU Leuven) (submittedVersion, cc-by)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UCL Discovery (University College London) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
  • Research Explorer (The University of Manchester) (submittedVersion, cc-by)
  • St Andrews Research Repository (St Andrews Research Repository) (submittedVersion, cc-by)
  • Tampere University Institutional Repository (Tampere University) (submittedVersion, cc-by)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Apollo (cc-by)
Funders
  • Wellcome Trust (103858/Z/14/Z, 077012/Z/05/Z, 077012)
  • Francis Crick Institute (10202)
  • National Institute for Health Research Health Protection Research Unit
  • Cancer Research UK (20406, 18387, 14835)
  • National Institute for Health and Care Research
  • Newcastle University
  • Rosetrees Trust (M46‐F1, M23-F1)
  • Public Health England
  • University College London Hospitals NHS Foundation Trust
  • Medical Research Council (MR/L016265/1)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
  • Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
Keywords
ionizing radiation, mutational signatures, secondary malignancies, somatic mutations, small deletions, microhomology, driver mutations, DNA damage, carcinogenesis
MeSH terms
Breast Neoplasms, DNA Damage, Female, Humans, Male, Mutation, Prostatic Neoplasms, Radiation, Ionizing, Osteosarcoma, Neoplasms, Second Primary, Gene Deletion, Germ-Line Mutation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.